Compare AIRG & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRG | AARD |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.3M | 85.7M |
| IPO Year | 2016 | N/A |
| Metric | AIRG | AARD |
|---|---|---|
| Price | $6.94 | $3.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $6.25 | ★ $15.29 |
| AVG Volume (30 Days) | 115.8K | ★ 164.9K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,779,000.00 | N/A |
| Revenue This Year | $10.31 | N/A |
| Revenue Next Year | $20.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.00 | $3.35 |
| 52 Week High | $7.39 | $17.94 |
| Indicator | AIRG | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 37.56 |
| Support Level | $3.93 | $3.35 |
| Resistance Level | $7.39 | $4.39 |
| Average True Range (ATR) | 0.37 | 0.57 |
| MACD | -0.04 | -0.12 |
| Stochastic Oscillator | 67.47 | 4.11 |
Airgain Incs a provider of advance wireless connectivity solutions. It is focused on delivering high-performance, cost-effective, and energy-efficient wireless solutions that enable rapid market deployment. It mission is to connect the world through integrated, and optimized wireless solutions. Companies' diverse product portfolio serves three primary markets: enterprise, automotive, and consumer. While historically recognized for high-performance radio frequency (RF) components, Airgain is increasingly delivering integrated, system-level connectivity solutions that combine hardware, software, and cloud management. The enterprise market demands reliable wireless access across diverse settings, including smart cities, campuses, stadiums, transportation hubs, utilities, buildings suburbs.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.